|
|
|
|
| LEADER |
00000cam a22000004a 4500 |
| 001 |
4414113 |
| 003 |
ICU |
| 005 |
20031020150800.0 |
| 008 |
991208s2000 sz a b 001 0 eng |
| 010 |
|
|
|a 99088881
|
| 020 |
|
|
|a 3805569491 (alk. paper)
|
| 035 |
|
|
|a MDNM100908975-B
|
| 035 |
|
|
|a 90059831
|
| 040 |
|
|
|a DNLM
|c DNLM
|d DNLM
|d OCoLC
|d OrLoB-B
|
| 042 |
|
|
|a pcc
|
| 060 |
0 |
0 |
|a 2000 D-653
|
| 060 |
1 |
0 |
|a WD 305
|b B615 2000
|
| 245 |
0 |
0 |
|a Biologic and gene therapy of autoimmune disease /
|c volume editor, C.G. Fathman.
|
| 260 |
|
|
|a Basel ;
|a New York :
|b Karger,
|c 2000.
|
| 300 |
|
|
|a 223 p. :
|b ill.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|0 http://id.loc.gov/vocabulary/contentTypes/txt
|
| 337 |
|
|
|a unmediated
|b n
|2 rdamedia
|0 http://id.loc.gov/vocabulary/mediaTypes/n
|
| 338 |
|
|
|a volume
|b nc
|2 rdacarrier
|0 http://id.loc.gov/vocabulary/carriers/nc
|
| 440 |
|
0 |
|a Current directions in autoimmunity
|v vol. 2
|
| 504 |
|
|
|a Includes bibliographical references and indexes.
|
| 505 |
0 |
0 |
|t Oral Tolerance as a Treatment Modality for Autoimmune Diseases /
|r C. C. Whitacre and K. A. Campbell --
|t Anti-CD4 Monoclonal Antibody Therapy in Human Autoimmune Diseases /
|r H. Schulze-Koops and P. E. Lipsky --
|t Novel Concepts of Tumor Necrosis Factor Action in Autoimmune Pathology /
|r D. S. Riminton and J. D. Sedgwick --
|t Anti-TNF[alpha] Therapy in Rheumatoid Arthritis - Current and Future Directions /
|r P. C. Taylor, R. O. Williams and R. N. Maini --
|t Cytokine-Directed Targeting in Chronic Arthritis /
|r W. B. van den Berg, L. A. B. Joosten and E. Lubberts --
|t Interleukin-10: Therapeutic Prospects in Rheumatoid Arthritis /
|r E. W. St. Clair --
|t Immunomodulation of Crohn's Disease /
|r S. J. H. van Deventer --
|t Retroviral and Lentiviral Gene Therapy for Autoimmune Disease /
|r R. Smith and G. P. Nolan --
|t Application of Gene Therapy in Autoimmune Disease /
|r C. G. Fathman and C. M. Seroogy --
|t DNA Vaccination in the Treatment of Autoimmune Disease /
|r H. Garren and L. Steinman.
|
| 583 |
1 |
|
|a committed to retain
|c 20170930
|d 20421213
|f HathiTrust
|5 ICU
|
| 650 |
1 |
2 |
|a Autoimmune Diseases
|x therapy.
|
| 650 |
2 |
2 |
|a Biological Therapy
|x methods.
|
| 650 |
2 |
2 |
|a Gene Therapy
|x methods.
|
| 650 |
|
7 |
|a Autoimmune diseases
|x Immunotherapy.
|2 fast
|0 http://id.worldcat.org/fast/fst00822669
|
| 650 |
|
7 |
|a Biological response modifiers.
|2 fast
|0 http://id.worldcat.org/fast/fst00832312
|
| 700 |
1 |
|
|a Fathman, C. Garrison.
|0 http://id.loc.gov/authorities/names/n83007209
|1 http://viaf.org/viaf/25970682
|
| 901 |
|
|
|a ToCBNA
|
| 903 |
|
|
|a HeVa
|
| 903 |
|
|
|a Hathi
|
| 035 |
|
|
|a (OCoLC)43051565
|
| 929 |
|
|
|a cat
|
| 999 |
f |
f |
|i b4d9bb4e-61a0-50fd-869f-f27e82d69e7d
|s 00221fea-8a85-5998-9d4f-9914460c0695
|
| 928 |
|
|
|t Library of Congress classification
|a RC600 .B56 2000
|l JCL
|c JCL-Sci
|i 4504094
|
| 927 |
|
|
|t Library of Congress classification
|a RC600 .B56 2000
|l JCL
|c JCL-Sci
|e CRERAR
|b 57470198
|i 7005896
|
